Palvella Therapeutics
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -21,829 | -21,562 | -17,806 | -10,975 |
EBIT | -21,829 | -19,562 | -13,728 | -10,975 |
Net Income | -24,643 | -21,870 | -15,767 | -12,714 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -14,428 | -12,845 | -10,864 | -4,926 |
Cash | 193,297 | 187,803 | 206,394 | 57,982 |
Basic Shares | 14,531 | 14,356 | 13,085 | 11,251 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $25,902 |
Gross Profit | 23,122 | |||
EBITDA | -35,897 | -13,117 | 18,691 | -30,497 |
EBIT | -35,897 | -14,095 | -11,869 | -33,277 |
Net Income | -41,715 | -17,434 | 18,691 | -33,277 |
Net Change In Cash | 0 | 0 | 0 | 25,902 |
Free Cash Flow | -25,006 | -10,840 | -13,703 | -14,840 |
Cash | 57,982 | 83,602 | 7,350 | 16,053 |
Basic Shares | 11,251 | 2,226 | 1,268 | 930 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | -$1.70 |
2026-06-30 | -$1.52 |
2026-03-31 | -$1.20 |
2025-12-31 | -$1.08 |